Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.20.2
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2020
Stockholders' Equity  
Summary of restricted stock award activity The following table summarizes restricted stock award activity for the nine months ended September 30, 2020:

Weighted Average 

Number of

Grant Date Fair

    

Shares

    

Value  

Non-vested at December 31, 2019

3,303,839

$

4.29

Granted

1,107,340

2.39

Vested

(397,980)

4.31

Non-vested at September 30, 2020

4,013,199

$

3.77

Summary of stock option award activity

The following table summarizes stock option award activity for the nine months ended September 30, 2020:

Weighted Average 

Remaining

Weighted Average 

 Contractual Life

    

Stock Options 

    

Exercise Price

    

(in years)

Outstanding as of December 31, 2019

160,000

$

3.64

8.56

Granted

60,000

2.04

Outstanding as of September 30, 2020

220,000

$

3.20

8.29

Summary of warrant activities

A summary of warrant activities for the nine months ended September 30, 2020 is presented below:

Weighted Average 

Remaining

Weighted Average 

Contractual Life

    

Warrants 

    

Exercise Price 

    

(in years)

Outstanding as of December 31, 2019

4,207,447

$

6.81

1.25

Exercised

(102,742)

0.13

Expired

(880,250)

7.00

Outstanding as of September 30, 2020

3,224,455

$

6.97

0.19

Summary of stock-based compensation expense

The following table summarizes stock-based compensation expense for the three and nine  months ended September 30, 2020 and 2019 ($ in thousands):

For the three months ended September 30, 

For the nine months ended September 30, 

    

2020

    

2019

    

2020

    

2019

Research and development

$

157

$

179

$

462

$

559

General and administrative

 

568

654

 

1,633

1,885

Total stock-based compensation expense

$

725

$

833

$

2,095

$

2,444